JAPHET GAZTAMBIDE: Open Payments
NPI 1215074331 · SAINT CLOUD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,057 in 134 payments from 14 companies in 2025. Trend: 2023 $3,427 · 2024 $3,065 · 2025 $3,057
Food & beverage: $3,057
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 15 | $564 |
| ABBVIE INC. | 31 | $434 |
| Neurocrine BioSciences, Inc. | 11 | $352 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $344 |
| E.R. Squibb & Sons, L.L.C. | 9 | $332 |
| Otsuka America Pharmaceutical, Inc. | 16 | $292 |
| Janssen Pharmaceuticals, Inc | 17 | $263 |
| Alkermes, Inc. | 13 | $222 |
| Vanda Pharmaceuticals Inc. | 2 | $147 |
| Tris Pharma Inc | 2 | $35 |
Products named: Auvelity, VRAYLAR, INGREZZA, CAPLYTA, COBENFY, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across FL — which companies pay providers there.
